Cognitive enhancing effect of Canagliflozin in aluminum-induced rat model of Alzheimer's-like disease: Cross-talk between Amyloid-Β and BDNF/GSK-3β signaling.
📄 Abstract
The strong relationship between Alzheimer's Disease (AD) and diabetes mellitus (DM) is described by the term "type 3 diabetes". Canagliflozin (CAN), a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is an antidiabetic agent under investigation as a potential new treatment for AD due to its acetylcholinesterase (AChE) inhibitory properties. We aimed to examine the effect of CAN on the efficacy of the anti-acetylcholinesterase, rivastigmine (RIV), against aluminum chloride (AlCl
Confidence:
0.22
· 11 полей извлечено
Идентификация (6 полей)
Target
Canagliflozin
1.00
Alt. target
CAN
0.90
Protein family
Sodium-glucose co-transporter 2
0.90
Functional class
Transporter
0.80
Subcellular loc.
—
0.00
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Mechanism
—
0.00
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
—
0.00
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
—
0.00
Downstream (physiol)
—
0.00
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
Aluminum-induced rat model of Alzheimer's-like disease
0.90
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
Aluminum-induced rat model
0.90
Diet/model
Aluminum chloride (AlCl3) induced Alzheimer's-like disease
0.90
Клиника (11 полей)
Drug
Canagliflozin
1.00
Indication
Alzheimer's disease
0.90
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
preclinical
0.90
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
True
0.90